5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests


  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease
    • Dr Prem Chattoo, Gastroenterology and Hepatology
    • Other Contributors:
      • Dr Shamsul Alam Bhuiyan

    Dear Editor,

    We read this article with great interest. Thanks to author for submitting an interesting article. If the patients were on prednisolone or other immunosuppressive drugs then possible effects on CRC risk may be influenced by use of glucocorticoids or immunosuppressant. Question is which drugs really reduce the risk of colorectal cancer risk? As any effect of 5-ASA therapy on the risk of CRC could be me...

    Show More
    Conflict of Interest:
    None declared.